product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
c-Myc (D3N8F) Rabbit mAb
catalog :
13987
clonality :
monoclonal
host :
domestic rabbit
conjugate :
nonconjugated
clone name :
D3N8F
reactivity :
human, mouse
application :
western blot, immunohistochemistry - paraffin section, other
citations: 17
Published Application/Species/Sample/DilutionReference
  • western blot; human; 1:1000; loading ...; fig 1d, 3e
Dragan M, Nguyen M, Guzman S, Goertzen C, Brackstone M, Dhillo W, et al. G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer. Cell Death Dis. 2020;11:106 pubmed publisher
  • western blot; human; loading ...; fig 4g
Wang H, Chen Z, Wang S, Gao X, Qian M, Qiu W, et al. TGFβ1-induced beta-site APP-cleaving enzyme 2 upregulation promotes tumorigenesis through the NF-κB signalling pathway in human gliomas. Mol Oncol. 2020;14:407-425 pubmed publisher
  • western blot; human; loading ...; fig 1d, s2d, s2e, s2f
Lin Q, Chen X, Meng F, Ogawa K, Li M, Song R, et al. ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis. Mol Cancer. 2019;18:156 pubmed publisher
  • western blot; mouse; 1:1000; fig 5f
Morabito M, Larcher M, Cavalli F, Foray C, Forget A, Mirabal Ortega L, et al. An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma. EMBO Mol Med. 2019;11:e9830 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 5c
Wang S, Yao F, Lu X, Li Q, Su Z, Lee J, et al. Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. Am J Cancer Res. 2019;9:1161-1171 pubmed
  • western blot; mouse; loading ...; fig 3c
Simula L, Pacella I, Colamatteo A, Procaccini C, Cancila V, Bordi M, et al. Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming. Cell Rep. 2018;25:3059-3073.e10 pubmed publisher
  • immunohistochemistry - paraffin section; mouse; fig 7c
Andricovich J, Perkail S, Kai Y, Casasanta N, Peng W, Tzatsos A. Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors. Cancer Cell. 2018;33:512-526.e8 pubmed publisher
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 3f
Akiel M, Guo C, Li X, Rajasekaran D, Mendoza R, Robertson C, et al. IGFBP7 Deletion Promotes Hepatocellular Carcinoma. Cancer Res. 2017;77:4014-4025 pubmed publisher
  • western blot; mouse; loading ...; fig s5e
Genovese G, Carugo A, TEPPER J, Robinson F, Li L, Svelto M, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017;542:362-366 pubmed publisher
  • other; human; loading ...; fig 6-s3
Skene P, Henikoff S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. elife. 2017;6: pubmed publisher
  • western blot; human; loading ...; fig 5i
Liang J, Cao R, Zhang Y, Xia Y, Zheng Y, Li X, et al. PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. Nat Commun. 2016;7:12431 pubmed publisher
  • western blot; human; 1:1000; fig 4b,5e,7b
Grinshtein N, Rioseco C, Marcellus R, UEHLING D, Aman A, Lun X, et al. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget. 2016;7:59360-59376 pubmed publisher
Wang M, Nagle R, Knudsen B, Cress A, Rogers G. Centrosome loss results in an unstable genome and malignant prostate tumors. Oncogene. 2019;: pubmed publisher
Murakami S, Nemazanyy I, White S, Chen H, Nguyen C, Graham G, et al. A Yap-Myc-Sox2-p53 Regulatory Network Dictates Metabolic Homeostasis and Differentiation in Kras-Driven Pancreatic Ductal Adenocarcinomas. Dev Cell. 2019;51:113-128.e9 pubmed publisher
Ligorio M, Sil S, Malagon Lopez J, Nieman L, Misale S, Di Pilato M, et al. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell. 2019;: pubmed publisher
Weltner J, Balboa D, Katayama S, Bespalov M, Krjutskov K, Jouhilahti E, et al. Human pluripotent reprogramming with CRISPR activators. Nat Commun. 2018;9:2643 pubmed publisher
Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285-295 pubmed publisher
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.